{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:19:41Z","timestamp":1764177581853,"version":"3.46.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T00:00:00Z","timestamp":1725580800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy Nucleic Acids"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.omtn.2024.102330","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T20:16:02Z","timestamp":1727208962000},"page":"102330","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Allele-specific CRISPR-Cas9 editing inactivates a single-nucleotide variant associated with collagen VI muscular dystrophy"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9038-7506","authenticated-orcid":false,"given":"Yoshitsugu","family":"Aoki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.omtn.2024.102330_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102269","article-title":"Allele-specific CRISPR\/Cas9 editing inactivates a single nucleotide variant associated with collagen VI muscular dystrophy","author":"Bolduc","year":"2024","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/j.omtn.2024.102330_bib2","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/nrneurol.2011.81","article-title":"The collagen VI-related myopathies: muscle meets its matrix","volume":"7","author":"B\u00f6nnemann","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.omtn.2024.102330_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1126\/science.aad5177","article-title":"In\u00a0vivo gene editing in dystrophic mouse muscle and muscle stem cells","volume":"351","author":"Tabebordbar","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2024.102330_bib4","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1126\/science.aad5143","article-title":"In\u00a0vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy","volume":"351","author":"Nelson","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.omtn.2024.102330_bib5","doi-asserted-by":"crossref","first-page":"4410","DOI":"10.3390\/ijms23084410","article-title":"CRISPR\/Cas9-Mediated Allele-Specific Disruption of a Dominant COL6A1 Pathogenic Variant Improves Collagen VI Network in Patient Fibroblasts","volume":"23","author":"L\u00f3pez-M\u00e1rquez","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.omtn.2024.102330_bib6","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nbt.2884","article-title":"Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype","volume":"32","author":"Yin","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.omtn.2024.102330_bib7","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.ymthe.2023.11.027","article-title":"Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells","volume":"32","author":"Cattaneo","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.omtn.2024.102330_bib8","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nature17664","article-title":"Efficient introduction of specific homozygous and heterozygous mutations using CRISPR\/Cas9","volume":"533","author":"Paquet","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.omtn.2024.102330_bib9","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.gendis.2023.02.027","article-title":"Clinical applications of the CRISPR\/Cas9 genome-editing system: Delivery options and challenges in precision medicine","volume":"11","author":"Khoshandam","year":"2023","journal-title":"Genes Dis."},{"key":"10.1016\/j.omtn.2024.102330_bib10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1038\/s41591-018-0326-x","article-title":"Identification of preexisting adaptive immunity to Cas9 proteins in humans","volume":"25","author":"Charlesworth","year":"2019","journal-title":"Nat Med."}],"container-title":["Molecular Therapy Nucleic Acids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124002178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2162253124002178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:16:19Z","timestamp":1764177379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2162253124002178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":10,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S2162253124002178"],"URL":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102330","relation":{},"ISSN":["2162-2531"],"issn-type":[{"type":"print","value":"2162-2531"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Allele-specific CRISPR-Cas9 editing inactivates a single-nucleotide variant associated with collagen VI muscular dystrophy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy Nucleic Acids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102330","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.omtn.2024.102269","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc. on behalf of The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102330"}}